Cogent Biosciences, Inc...announced that the results from the Phase 3 PEAK trial have been selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL, May 29-June 2, 2026.

bezuclastinib (PLX9486) - Cogent Biosci

Apr 21, 2026